SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib

被引：0
|
作者：
Ahn, M. [1 ]
Cantarini, M. [2 ]
Frewer, P. [2 ]
Hawkins, G. [2 ]
Peters, J. [2 ]
Howarth, P. [2 ]
Ahmed, G. [3 ]
Sahota, T. [3 ]
Hartmaier, R. [4 ]
Li-Sucholeiki, X. [4 ]
Oxnard, G. [5 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Astrazeneca, Cambridge, England
[3] Astrazeneca, Quantitat Clin Pharmacol, Early Clin Dev, Imed Biotech Unit, Cambridge, England
[4] Astrazeneca, Waltham, MA USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
MET; Non-Small Cell Lung Cancer; resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-134
引用
收藏
页码：S415 / S416
页数：2
相关论文
共 50 条
  • [1] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
    Oxnard, Geoffrey R.
    Cantarini, Mireille
    Frewer, Paul
    Hawkins, George
    Peters, Jane
    Howarth, Paul
    Ahmed, Ghada F.
    Sahota, Tarjinder
    Hartmaier, Ryan
    Li-Sucholeiki, Xiaocheng
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor
    Mao, Y.
    Huang, Z.
    Cai, D.
    Lou, R.
    Shen, C.
    Wang, X.
    Liu, Y.
    Qi, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S638 - S638
  • [3] SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
    Zhou, Q.
    Li, J.
    Wang, J.
    Yang, L.
    Fang, J.
    Dong, X.
    Yi, T.
    Min, X.
    Xu, F.
    Chen, J.
    Zhong, D.
    Bai, J.
    Liu, L.
    Zeng, A.
    Tang, J.
    Wu, H.
    Luo, X.
    Yu, J.
    Su, W.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S429
  • [4] Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
    Piotrowska, Zofia
    Liu, Stephen V.
    Muzikansky, Alona
    Marcoux, Nicolas
    Banwait, Mandeep
    Stevens, Sara
    Goodwin, Kelly
    Lafferty, Tracey E.
    Ackil, Jennifer
    Krueger, Elizabeth A.
    Heist, Rebecca Suk
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Hata, Aaron N.
    Shaw, Alice Tsang
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
    Han, J-Y.
    Sequist, L. V.
    Ahn, M-J.
    Cho, B. C.
    Yu, H.
    Kim, S-W.
    Yang, J. C-H.
    Lee, J. S.
    Su, W-C.
    Kowalski, D.
    Orlov, S.
    Cantarini, M.
    Verheijen, R. B.
    Mellemgaard, A.
    Frewer, P.
    Ou, X.
    Oxnard, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [7] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, T. M.
    Guarneri, V.
    Jye, V. P.
    Khaw, L. B.
    Yang, J. -J.
    Wislez, M.
    Huang, C.
    Kin, L. Chong
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nhung, N.
    Chia, P. L.
    De Marinis, F.
    Raskin, J.
    Zhou, Q.
    Finochhiaro, G.
    Le, X.
    Tan, D.
    Brutlach, S.
    O'Brate, A.
    Adrian, S.
    Berghoff, K.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
  • [8] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jin-ji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Ye Mun
    Hayashi, Hidetoshi
    Nhung Nguyen
    Chia, Puey Ling
    de Marinis, Filippo
    Raskin, Jo
    Zhou, Qinghua
    Finocchiaro, Giovanna
    Le, Xiuning
    Tan, Daniel
    O'Hara, Richard M., Jr.
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E38 - E38
  • [9] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [10] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
    Ahn, M.
    Han, J.
    Sequist, L.
    Cho, B. C.
    Lee, J. S.
    Kim, S.
    Su, W.
    Tsai, C.
    Yang, J. C.
    Yu, H.
    Horn, L.
    Lee, K.
    Haddad, V.
    Frigault, M.
    Ahmed, G.
    Yang, L.
    Ghiorghiu, D.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1768 - S1768
12345